ANI Pharmaceuticals Inc
Company Profile
Business description
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Contact
210 Main Street West
BaudetteMN56623
USAT: +1 218 634-3500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
897
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors overly negative on cheap ASX share
stocks
Overvalued US AI play reports earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.60 | 29.50 | 0.33% |
| CAC 40 | 8,175.89 | 26.39 | 0.32% |
| DAX 40 | 24,497.89 | 7.48 | 0.03% |
| Dow JONES (US) | 48,057.57 | 5.72 | -0.01% |
| FTSE 100 | 9,969.08 | 37.70 | 0.38% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,337.11 | 95.12 | 0.41% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,860.72 | 15.22 | 0.22% |
| S&P/ASX 200 | 8,727.80 | 27.10 | 0.31% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |